LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME’s America’s Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD’s continued revenue growth, financial stability, and emerging leadership position in the health technology sector.
“Inclusion on these lists of North America’s fastest-growing companies is a testament to the strength of our integrated telehealth platform and our ability to meet the increasing demand for accessible, high-quality virtual healthcare. With a commitment to expanding our product and service offerings, we’ve successfully tapped into large, high-growth markets such as weight management, mental health, and men’s and women’s hormone replacement therapy,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.
“LifeMD's progress is powered by our ongoing investment in a differentiated enterprise platform, including our state-of-the-art affiliated compounding pharmacy; expanded reach through insurance coverage; and our growing network of strategic employer, pharma, and commercial partnerships. We remain deeply committed to delivering innovative, affordable solutions that adapt to the evolving healthcare landscape and drive long-term value for our patients and our shareholders,” Mr. Schreiber added.
“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the Top 10 are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”
LifeMD’s listing on TIME's America’s Growth Leaders of 2026 ranking, which recognizes companies based on factors such as growth performance, financial stability, and stock performance, underscores its position among the nation’s most dynamic and successful companies, distinguished by a unique combination of innovation, market expansion, and financial strength.
About the 2025 Deloitte Technology Fast 500
Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners were selected based on percentage fiscal year revenue growth from 2021 to 2024.
To be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology that significantly contributes to the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million, with a growth rate of 50% or greater. Additionally, companies must be in business for a minimum of four years and be headquartered within North America (United States and Canada).
Please see www.deloitte.com/us/about for a detailed description of their legal structure.
About TIME’s list of America’s Growth Leaders of 2026
The inaugural TIME’s list of America’s Growth Leaders of 2026, developed in partnership with Statista, identifies 500 U.S. publicly traded companies that have demonstrated exceptional five-year growth performance, financial health, and resilient stock performance. More information on the methodology used can be found on TIME’s website.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, spanning primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
